Immuneering Corp Stock Forward View - Double Exponential Smoothing
| IMRX Stock | USD 5.05 -0.40 -7.34% |
Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter -0.34 | EPS Estimate Current Year -1.19 | EPS Estimate Next Year -1.53 | Wall Street Target Price 17 | EPS Estimate Current Quarter -0.31 |
This view relates Immuneering Corp's headline activity to recent price response context. Options and short interest provide context for sentiment around Immuneering Corp in this section.
For a complete overview, review Net Debt To E B I T D A and Intangibles To Total Assets.
Immuneering Corp Implied Volatility | 2.09 |
Implied volatility in Immuneering Corp's options does not predict direction - it measures magnitude. An investor expecting a large move in Immuneering Corp stock in either direction may benefit from strategies that profit from volatility expansion.
The Double Exponential Smoothing forecasted value of Immuneering Corp on the next trading day is expected to be 5.06 with a mean absolute deviation of 0.30 and the sum of the absolute errors of 17.88.Immuneering Corp after-hype prediction price | $ 5.03 |
The sentiment view is a companion to forecasting, technical studies, analyst estimates, and earnings trends.
Immuneering | Build AI portfolio with Immuneering Stock |
Open Interest Map for Immuneering Options 2026-05-15
The open interest measure summarizes active contracts for Immuneering Corp and can be paired with trend context.
Immuneering Corp Additional Predictive Modules
Most predictive techniques to examine Immuneering price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Immuneering using various technical indicators. When you analyze Immuneering charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Double Exponential Smoothing Price Forecast For the 16th of March 2026
Given 90 days horizon, the Double Exponential Smoothing forecasted value of Immuneering Corp on the next trading day is expected to be 5.06 with a mean absolute deviation of 0.30 , mean absolute percentage error of 0.31 , and the sum of the absolute errors of 17.88 .Please note that although there have been many attempts to predict Immuneering Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Immuneering Corp's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Immuneering Corp | Immuneering Corp Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Immuneering Corp uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Immuneering Corp stock data series using in forecasting. Note that when a statistical model is used to represent Immuneering Corp stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0921 |
| MAD | Mean absolute deviation | 0.303 |
| MAPE | Mean absolute percentage error | 0.0566 |
| SAE | Sum of the absolute errors | 17.8752 |
Experienced Immuneering Corp's investors use mean reversion as a complement to momentum analysis: momentum identifies the trend; mean reversion identifies when that trend has extended beyond sustainable levels.
After-Hype Price Density Analysis
This probability distribution for Immuneering Corp is built from Monte Carlo simulations that incorporate Immuneering Corp's historical volatility, mean reversion tendencies, and jump risk. The resulting distribution captures a broader range of Immuneering Corp outcomes than simple linear.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The boundaries derived from Immuneering Corp's historical news analysis represent the range within which Immuneering Corp's price has typically settled after comparable headline events. Immuneering Corp's after-hype downside and upside margins for the prediction period are 0.25 and 12.47, respectively. Outcomes outside these boundaries are less common but not rare for Immuneering Corp.
Current Value
The after-hype framework applied to Immuneering Corp assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Immuneering Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immuneering Corp backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Immuneering Corp, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 7.44 | 0.02 | 0.02 | 16 Events | 7 Events | In 16 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
5.05 | 5.03 | 0.40 |
|
Hype Timeline
Immuneering Corp is currently traded for 5.05. The company has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.02. Immuneering is projected to decline in value after the next headline, with the price expected to drop to 5.03. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.4%, whereas the daily expected return is currently at 0.11%. The volatility of related hype on Immuneering Corp is about 3542.86%, with the expected price after the next announcement by competition of 5.07. About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immuneering Corp recorded a loss per share of 1.79. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in 16 days. Cross-verify projections for Immuneering Corp using Historical Fundamental Analysis of Immuneering Corp. The view supplies historical context for the projection discussion.Related Hype Analysis
Understanding Immuneering Corp's position within its competitive set helps investors assess whether news affecting a peer is a headwind or tailwind for Immuneering Corp. This distinction requires knowledge of the competitive dynamics specific to Immuneering Corp's industry.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| FHTX | Foghorn Therapeutics | 0.32 | 11 per month | 3.57 | 0.06 | 8.60 | -5.54 | 36.56 | |
| PYXS | Pyxis Oncology | 0.08 | 7 per month | 0.00 | -0.11 | 9.49 | -9.40 | 51.54 | |
| NAUT | Nautilus Biotechnology | 0.25 | 7 per month | 4.58 | 0.07 | 9.29 | -7.21 | 39.09 | |
| ZURA | Zura Bio Limited | -0.18 | 9 per month | 4.20 | 0.17 | 9.32 | -7.00 | 33.15 | |
| HUMA | Humacyte | -0.03 | 9 per month | 4.69 | 0.01 | 11.11 | -8.11 | 43.72 | |
| ASMB | Assembly Biosciences | -0.19 | 13 per month | 0.00 | -0.06 | 5.85 | -7.15 | 19.10 | |
| ENTA | Enanta Pharmaceuticals | 0.32 | 8 per month | 0.00 | -0.02 | 5.41 | -5.36 | 20.18 | |
| ARCT | Arcturus Therapeutics Holdings | 0.36 | 9 per month | 0.00 | -0.02 | 6.53 | -5.23 | 17.23 | |
| TNYA | Tenaya Therapeutics | -0.03 | 10 per month | 0.00 | -0.03 | 8.57 | -10.71 | 47.63 | |
| TRDA | Entrada Therapeutics | 1.20 | 10 per month | 3.18 | 0.09 | 6.40 | -6.72 | 14.87 |
Other Forecasting Options for Immuneering Corp
Understanding Immuneering Corp's price movement is a prerequisite for any investor considering Immuneering as a position. Immuneering Stock price charts are frequently cluttered with noise that can interfere with accurate interpretation.Immuneering Corp Related Equities
The following equities are related to Immuneering Corp within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Immuneering Corp against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Immuneering Corp Market Strength Events
For traders and investors in Immuneering Corp, market strength indicators offer a quantitative framework for evaluating the stock's responsiveness to market conditions. These tools help identify when trading Immuneering Corp shares is most likely to generate favorable returns.
Immuneering Corp Risk Indicators
Analyzing Immuneering Corp's risk indicators provides a critical input for price forecasting and investment risk management. By quantifying the risk in Immuneering Corp's investment, investors can make more informed decisions about their exposure and hedging strategies.
| Mean Deviation | 3.94 | |||
| Standard Deviation | 7.26 | |||
| Variance | 52.76 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Immuneering Corp
Coverage intensity for Immuneering Corp matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Immuneering Corp Short Properties
Short sentiment tied to Immuneering Corp matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 44 M | |
| Cash And Short Term Investments | 172.8 M |
More Resources for Immuneering Stock Analysis
Reviewing Immuneering Corp commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Immuneering Stock:Cross-verify projections for Immuneering Corp using Historical Fundamental Analysis of Immuneering Corp. The view supplies historical context for the projection discussion. Our How to Buy Immuneering Stock guide explains the steps to invest in Immuneering Corp stock.Analysis related to Immuneering Corp should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Investors evaluate Immuneering Corp using market value and book value, each describing different facets of the business. Immuneering Corp's market capitalization is 326.08 M. A P/B ratio of 1.43 indicates the market values Immuneering Corp above its accounting book value. Enterprise value stands at 102.43 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Immuneering Corp differs from its quoted price, since each reflects a different lens. For Immuneering Corp, key inputs include a P/B ratio of 1.43, ROE of -43.12%, and revenue of 455. Trading price represents the transaction level agreed by market participants.